Purpose: To assess the value of multi-tumor marker protein chips in the diagnosis and treatment of ovariancancer. Materials and Methods: Twelve tumor markers (CA19-9, NSE, CEA, CA242, CK19, β-HCG, AFP, SCC,c-PSA, CA125, CA724 and CA15-3) were detected by protein biochip in 220 patients with ovarian carcinomas,205 with benign ovarian tumors and 200 healthy subjects. Results: The positivity rate was obviously higher inovarian cancer (77.7%), than that in the benign cases (26.3%, p<0.01) and healthy subjects (4.5%, p<0.01). Serumlevels of tumor markers were furthermore significantly higher in cases with lymph node metastasis (86.8%) thanthose without metastasis (44.7%), p<0.01. Conclusions: Multi-tumor marker protein chips provide importantassistance in the diagnosis and treatment evaluation in ovarian cancers.
(2014). Clinical Applicability of Multi-Tumor Marker Protein Chips for Diagnosing Ovarian Cancer. Asian Pacific Journal of Cancer Prevention, 15(19), 8409-8411.
MLA
. "Clinical Applicability of Multi-Tumor Marker Protein Chips for Diagnosing Ovarian Cancer". Asian Pacific Journal of Cancer Prevention, 15, 19, 2014, 8409-8411.
HARVARD
(2014). 'Clinical Applicability of Multi-Tumor Marker Protein Chips for Diagnosing Ovarian Cancer', Asian Pacific Journal of Cancer Prevention, 15(19), pp. 8409-8411.
VANCOUVER
Clinical Applicability of Multi-Tumor Marker Protein Chips for Diagnosing Ovarian Cancer. Asian Pacific Journal of Cancer Prevention, 2014; 15(19): 8409-8411.